Biotech Money, Where Art Thou?

 
• By Chris Morrison

While public biotech funding in the US in 2003 outpaced private funding by more than five to one, the smaller financing picture in Europe tells a different story.

US biotech funding continues to dramatically outpace Europe on all fronts—public and private, product and platform, large and small. No surprise there: most of Europe's biotechs are far less mature than their US counterparts, Europe has fewer specialist investors, and general risk aversion means there's barely any generalist investor interest in the sector.

But while public biotech funding in the US in 2003—at over $11 billion according to Windhover's Strategic Intelligence Systems Databases—outpaced...

More from Global Vision

More from In Vivo

Podcast: Scancell’s Cancer Vaccine Progress With NHS Partnership

 
• By Jo Shorthouse

In the latest podcast interview, Phil L'Huillier, CEO of Scancell, discussed the company's work in cancer vaccine development, and its selection as the first British biotech to be a part of the NHS Cancer Vaccine Launch Pad.

Geopolitical Volatility Not Dimming A Healthy Mid-Term Outlook For Life Sciences Deals

 
• By Ashley Yeo

New report by global law firm Taylor Wessing and Bayes Business School forecasts a steadily increasing volume of major life sciences M&A in the coming five years, but highlights concerns over cybersecurity and unrealistic valuations. Taylor Wessing partner Andrew Edge spoke to In Vivo.

Navigating the GLP-1 Opportunity In China: Strategic Imperatives For Western Pharma

 
• By Jo Shorthouse

The Chinese appetite for GLP-1s is noticeable. While the market opportunity for western pharma is huge, so are the strategic market access challenges, though not unsurmountable, L.E.K. Consulting told In Vivo.